全文获取类型
收费全文 | 75304篇 |
免费 | 5362篇 |
国内免费 | 163篇 |
专业分类
耳鼻咽喉 | 595篇 |
儿科学 | 2804篇 |
妇产科学 | 2479篇 |
基础医学 | 9158篇 |
口腔科学 | 1008篇 |
临床医学 | 13220篇 |
内科学 | 13434篇 |
皮肤病学 | 1113篇 |
神经病学 | 6916篇 |
特种医学 | 1354篇 |
外国民族医学 | 33篇 |
外科学 | 6409篇 |
综合类 | 969篇 |
一般理论 | 129篇 |
预防医学 | 10559篇 |
眼科学 | 857篇 |
药学 | 4207篇 |
1篇 | |
中国医学 | 103篇 |
肿瘤学 | 5481篇 |
出版年
2023年 | 447篇 |
2022年 | 633篇 |
2021年 | 1430篇 |
2020年 | 1044篇 |
2019年 | 1717篇 |
2018年 | 1917篇 |
2017年 | 1340篇 |
2016年 | 1568篇 |
2015年 | 1701篇 |
2014年 | 2261篇 |
2013年 | 3668篇 |
2012年 | 5193篇 |
2011年 | 5466篇 |
2010年 | 2945篇 |
2009年 | 2724篇 |
2008年 | 4894篇 |
2007年 | 5453篇 |
2006年 | 5286篇 |
2005年 | 5102篇 |
2004年 | 4923篇 |
2003年 | 4669篇 |
2002年 | 4407篇 |
2001年 | 600篇 |
2000年 | 449篇 |
1999年 | 606篇 |
1998年 | 993篇 |
1997年 | 757篇 |
1996年 | 682篇 |
1995年 | 592篇 |
1994年 | 566篇 |
1993年 | 559篇 |
1992年 | 384篇 |
1991年 | 327篇 |
1990年 | 312篇 |
1989年 | 279篇 |
1988年 | 272篇 |
1987年 | 258篇 |
1986年 | 244篇 |
1985年 | 289篇 |
1984年 | 296篇 |
1983年 | 303篇 |
1982年 | 381篇 |
1981年 | 361篇 |
1980年 | 305篇 |
1979年 | 175篇 |
1978年 | 163篇 |
1977年 | 175篇 |
1976年 | 161篇 |
1975年 | 135篇 |
1974年 | 124篇 |
排序方式: 共有10000条查询结果,搜索用时 9 毫秒
31.
Phase I study of high-dose cytosine arabinoside and etoposide in patients with advanced malignancies
Bayard L. Powell Hyman B. Muss Robert L. Capizzi Mary E. Caponera Douglas R. White Patricia J. Zekan James N. Atkins Don V. Jackson Jr. Frederick Richards II John B. Craig Julia M. Cruz Charles L. Spurr 《Cancer chemotherapy and pharmacology》1987,19(3):250-252
Summary Cytosine arabinsodie (ara-C) and etoposide (VP-16) display synergy in the laboratory. Twenty-six patients participated in a phase I study of high-dose ara-C in combination with VP-16. The dose of VP-16 was held constant at 50 mg/m2 as an intermittent infusion over 33 h; escalating doses of ara-C were given as infusions during hours 9–12 and 21–24. Myelosuppression was the dose-limiting toxicity and occurred with doses considerably less than those expected from studies of the two drugs as single agents. The suggested initial doses for phase II trials with this schedule are 750 mg/m2×2 doses of ara-C and 50 mg/m2 of VP-16. Nonhematologic toxicity was minimal; therefore, further dose escalation is feasible in patients in whom myelosuppression is acceptable.Supported in part by grants from the National Cancer Institute (CA-12197 and CA-09422) and the American Cancer Society CF-85-182 相似文献
32.
33.
34.
35.
Ann McPherson 《British medical journal》2005,330(7489):465-467
36.
Ann G Schwartz Geoffrey M Prysak Valerie Murphy Fulvio Lonardo Harvey Pass Jan Schwartz Sam Brooks 《Clinical cancer research》2005,11(20):7280-7287
PURPOSE: A role for estrogens in determining lung cancer risk and prognosis is suggested by reported sex differences in susceptibility and survival. Archival lung tissue was evaluated for the presence of nuclear estrogen receptor (ER)-alpha and ER-beta and the relationship between ER status, subject characteristics, and survival. EXPERIMENTAL DESIGN: Paraffin-embedded lung tumor samples were obtained from 214 women and 64 men from two population-based, case-control studies as were 10 normal lung autopsy samples from patients without cancer. Nuclear ER-alpha and ER-beta expression was determined by immunohistochemistry. Logistic regression was used to identify factors associated with ER positivity and Cox proportional hazards models were used to measure survival differences by ER status. RESULTS: Neither tumor (0 of 94) nor normal (0 of 10) lung tissue stained positive for ER-alpha. Nuclear ER-beta positivity was present in 61% of tumor tissue samples (170 of 278; 70.3% in men and 58.3% in women) and 20% of normal tissue samples (2 of 10; P = 0.01). In multivariate analyses, females were 46% less likely to have ER-beta-positive tumors than males (odds ratio, 0.54; 95% confidence interval, 0.27-1.08). This relationship was stronger and statistically significant in adenocarcinomas (odds ratio, 0.40; 95% confidence interval, 0.18-0.89). Women with ER-beta-positive tumors had a nonsignificant 73% (P = 0.1) increase in mortality, whereas men with ER-beta-positive tumors had a significant 55% (P = 0.04) reduction in mortality compared with those with ER-beta-negative tumors. CONCLUSIONS: This study suggests differential expression by sex and influence on survival in men of nuclear ER-beta in lung cancer, particularly in adenocarcinomas. 相似文献
37.
38.
39.
40.
OBJECTIVE: This article 1) provides an overview of formal Health Sciences Teaching Scholars Programs as presented in medical education literature and 2) presents information about an innovative multidiscipline Teaching Scholars Program. METHOD: Health Sciences Teaching Scholars Programs and similar programs were reviewed in the medical education literature to identify similar and dissimilar characteristics. The WVU Teaching Scholars Program highlighted in this article is presented with a discussion of goals, objectives, target audiences, course length, session frequency, program topics, learning methods, and assessments of the programs. A summary of the WVU Teaching Scholars Program and two Teaching Scholars Programs at McGill University and the University of Toronto were presented at the Association for American Medical Colleges (AAMC) annual meeting in 2006 for input from the general medical education audience. RESULTS: Comparisons of Health Sciences Teaching Scholars Programs reveal that successful programs are uniquely shaped by their educational environments. Scholars report that they value learning new teaching methods and improving their educational careers. CONCLUSION: Teaching Scholars Programs are valuable for the development of enhancing both teaching and scholarship in Health Sciences Programs and must adapt to the uniqueness of their respective educational environments and must continue to nurture scholars beyond graduation. 相似文献